Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

64% MMR achievement by 24 weeks across all efficacy evaluable patients The ASH presentation will be made available on the Terns Pharmaceuticals website simultaneously with the oral presentation by ...

Of 38 efficacy-evaluable patients, the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks, with 64% (18/28) achieving MMR and 100% (10/10) maintaining MMR. Also Read: ...

Investing.com -- Enliven Therapeutics (NASDAQ:ELVN) stock surged 7% Thursday after the biopharmaceutical company reported positive initial Phase 1b data for its chronic myeloid leukemia (CML) drug ...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...

Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a Phase 1b study of its chronic myeloid leukemia (CML) drug candidate, ...

Treatment-free remission (TFR) may be feasible in many patients with chronic myeloid leukaemia (CML), say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase ...

Good day, and thank you for standing by. Welcome to the Terns Pharmaceuticals TERN-701 December 2025 Data Update Conference Call. Please be advised that today's conference is being recorded. I would ...